Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment

Neuropsychopharmacology

Volumn 40, Issue 10, 2015, Pages 2409-2417

  Ahmed, Mohamed ^a   Cannon, Dara M ^a   Scanlon, Cathy ^a   Holleran, Laurena ^a   Schmidt, Heike ^a   McFarland, John ^a   Langan, Camilla ^a   McCarthy, Peter ^a   Barker, Gareth J ^b   Hallahan, Brian ^a   McDonald, Colm ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SCINTISCANNING; BRAIN SIZE; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); CORTICAL THINNING; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MEDIAL FRONTAL CORTEX; MEDIAL PREFRONTAL CORTEX; MEDICAL ASSESSMENT; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCHIZOPHRENIA; TEMPORAL CORTEX; TREATMENT RESPONSE; ATROPHY; BRAIN CORTEX; CASE CONTROL STUDY; COMPLICATION; DRUG EFFECTS; IMAGE PROCESSING; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PRESCHOOL CHILD; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; ATROPHY; CASE-CONTROL STUDIES; CEREBRAL CORTEX; CHILD, PRESCHOOL; CLOZAPINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84939252487     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.90     Document Type: Article

References (50)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revised. Washington, DC.
2. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). University of Iowa; 1984a.
3. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa; 1984b.
4. Bai O, Zhang H, Li XM (2004). Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 1010: 81-86.
5. Bardgett ME, Griffith MS, Foltz RF, Hopkins JA, Massie CM, O'Connell SM (2006). The effects of clozapine on delayed spatial alternation deficits in rats with hippocampal damage. Neurobiol Learn Mem 85: 86-94.
6. Cahn W, Hulshoff Pol HE, Lems EB, van Haren NE, Schnack HG, van der Linden JA et al (2002). Brain volume changes in first episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry 59: 1002-1010.
7. Cahn W, van Haren NE, Hulshoff Pol HE, Schnack HG, Caspers E, Laponder DA et al (2006). Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry 189: 381-382.
8. Crespo-Facorro B, Roiz-Santiáñez R, Pérez-Iglesias R, Pelayo-Terán JM, Rodríguez-Sánchez JM, Tordesillas-Gutiérrez D et al (2008). Effect of antipsychotic drugs on brain morphometry: a randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 32: 1936-1943.
9. Dale AM, Fischl B, Sereno MI (1999). Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 9: 179-194.
10. Davis KL, Buchsbaum MS, Shihabuddin L, Spiegel-Cohen J, Metzger M, Frecska E et al (1998). Ventricular enlargement in poor-outcome schizophrenia. Biol Psychiatry 43: 783-793.
11. de Bresser J, Portegies MP, Leemans A, Biessels GJ, Kappelle LJ, Viergever MA (2011). A comparison of MR based segmentation methods for measuring brain atrophy progression. Neuroimage 54: 760-768.
12. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 30: 1649-1661.
13. Ebdrup BH, Nørbak H, Borgwardt S, Glenthøj B (2013). Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Curr Med Chem 20: 438-447.
14. Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E (2008). The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am J Psychiatry 165: 1015-1023.
15. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33: 766-771.
16. First MB, Spitzer RL, Gibbon M, Williams JB (2002a). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute: New York.
17. First MB, Spitzer RL, Gibbon M, Williams JB (2002b). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). Biometrics Research, New York State Psychiatric Institute: New York.
18. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S (2013). Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 37: 1680-1691.
19. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W et al (1998). A follow-up magnetic resonance imaging study of schizophrenia: relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry 55: 145-152.
20. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS (2013). Brain volumes in schizophrenia: a meta-analysis in over 18000 subjects. Schizophr Bull 39: 1129-1138.
21. Halim ND, Weickert CS, McClintock BW, Weinberger DR, Lipska BK (2004). Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 29: 1063-1069.
22. Harrison PJ (1999). The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 122: 593-624.
23. Hirjak D, Wolf RC, Stieltjes B, Hauser T, Seidl U, Schröder J et al (2014). Cortical signature of neurological soft signs in recent onset schizophrenia. Brain Topogr 27: 296-306.
24. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M (2003). Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 60: 585-594.
25. Ho BC, Andreason NC, Ziebell S, Pierson R, Magnotta V (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 68: 128-137.
26. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
27. Kempton MJ, Stahl D, Williams SCR, DeLisi LE (2010). Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. Schizophr Res 120: 54-62.
28. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW (1994). Changes in caudate volume with neuroleptic treatment. Lancet 344: 1434.
29. Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA (2007). Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology 32: 1216-1223.
30. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS et al (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62: 361-370.
31. Mattai A, Chavez A, Greenstein D, Clasen L, Bakalar J, Stidd R et al (2010). Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia. Schizophr Res 116: 44-48.
32. Miller DD, Andreasen NC, O'Leary DS,Watkins GL, Boles Ponto LL, Hichwa RD (2001). Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol Psychiatry 49: 704-715.
33. Molina V, Sanz J, Sarramea F, Benito C, Palomo T (2004). Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients. Psychiatry Res 131: 45-56.
34. Molina V, Reig S, Sanz J, Palomo T, Benito C, Sanchez J et al (2005). Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr Res 80: 61-71.
35. Navari S, Dazzan P (2009). Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med 39: 1763-1777.
36. Nesvåg R, Lawyer G, Varnäs K, Fjell AM, Walhovd KB, Frigessi A et al (2008). Regional thinning of the cerebral cortex in schizophrenia: effects of diagnosis, age and antipsychotic medication. Schizophr Res 98: 16-28.
37. Pantelis C, Velakoulis D, McGorry P, Wood SJ, Suckling J, Phillips LJ et al (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361: 281-288.
38. Reuter M, Schmansky NJ, Rosas HD, Fischl B (2012). Withinsubject template estimation for unbiased longitudinal image analysis. Neuroimage 61: 1402-1418.
39. Scheepers FE, de Wied CC, Hulshoff Pol HE, van de Flier W, van der Linden JA, Kahn RS (2001). The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 24: 47-54.
40. Scherk H, Falkai P (2006). Effects of antipsychotics on brain structure. Curr Opin Psychiatry 19: 145-150.
41. Schuster C, Schuller AM, Paulos C, Namer I, Pull C, Danion JM et al (2012). Gray matter volume decreases in elderly patients with schizophrenia: a voxel-based morphometry study. Schizophr Bull 38: 796-802.
42. Smith SM, De Stefano N, Jenkinson M, Matthews PM (2001). Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 25: 466-475.
43. Smith SM, Nichols TE (2009). Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 44: 83-98.
44. Sporn AL, Greenstein DK, Gogtay N, Jeffries NO, Lenane M, Gochman P et al (2003). Progressive brain volume loss during adolescence in childhood-onset schizophrenia. Am J Psychiatry 160: 2181-2189.
45. Sprooten E, Papmeyer M, Smyth AM, Vincenz D, Honold S, Conlon GA et al (2013). Cortical thickness in first-episode schizophrenia patients and individuals at high familial risk: a cross-sectional comparison. Schizophr Res 151: 259-264.
46. van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Brans R, Carati I et al (2008). Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry 63: 106-113.
47. van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RC, Collins DL et al (2007). Focal gray matter changes in schizophrenia across the course of the illness: a 5-year followup study. Neuropsychopharmacology 32: 2057-2066.
48. van Haren NE, Schnack HG, Cahn W, van den Heuvel MP, Lepage C, Collins L et al (2011). Changes in cortical thickness during the course of illness in schizophrenia. Arch Gen Psychiatry 68: 871-880.
49. Vernon AC, Natesan S, Modo M, Kapur S (2011). Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry 69: 936-944.
50. Zipursky RB, Reilly TJ, Murray RM (2013). The myth of schizophrenia as a progressive brain disease. Schizophr Bull 39: 1363-1372.